Anika Therapeutics, Inc. (ANIK) Operating margin 2016–2025
Anika Therapeutics, Inc. (ANIK) operating margin by fiscal year — reported operating income divided by reported revenue.
-9.8%FY2025 · since FY2016: 49.0% → -9.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -9.8% | -5.5 pp |
| FY2024 | -4.3% | -5.0 pp |
| FY2023 | 0.7% | -2.5 pp |
| FY2022 | 3.2% | +1.5 pp |
| FY2021 | 1.8% | +23.5 pp |
| FY2020 | -21.7% | -51.6 pp |
| FY2019 | 29.9% | +9.3 pp |
| FY2018 | 20.6% | -19.7 pp |
| FY2017 | 40.3% | -8.6 pp |
| FY2016 | 49.0% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ANIK financial trends
ANIK RevenueANIK Net incomeANIK Net marginANIK Gross profitANIK Gross marginANIK Operating incomeANIK Operating cash flowANIK Free cash flowANIK Capital expendituresANIK Return on equityANIK Stock buybacksANIK Dividends paidANIK Total assetsANIK Total liabilitiesANIK Shareholders’ equityANIK overview →